ContextHuman papillomavirus (HPV) DNA testing of women having Papanicolaou (Pap)
smears showing atypical squamous cells of undetermined significance (ASCUS) has clinical …

ContextA Papanicolaou (Pap) test result of atypical squamous cells of undetermined
significance (ASCUS) presents a clinical challenge. Only 5% to 10% of women with ASCUS …

Human papillomavirus (HPV) DNA testing was recently approved by the Food and Drug
Administration for use as an adjunct to cytology for cervical cancer screening. To help …

Background: Results of cervical cytology screening showing atypical squamous cells of
undetermined significance (ASCUS) or low-grade squamous intraepithelial lesions (LSIL) …

ContextHuman papillomaviruses (HPVs) are known to cause most cervical cancer
worldwide, but the utility of HPV DNA testing in cervical cancer prevention has not been …

Background To determine whether testing for DNA of oncogenic human papillomaviruses
(HPV) is superior to the Papanicolaou (Pap) test for cervical-cancer screening, we …

Human papillomavirus (HPV) infection is a necessary cause of cervical cancer; HPV testing
capitalizes on this fact to maximize the clinical benefits of cervical screening and abnormal …

Despite its history of success in cancer screening, Pap cytology has important limitations,
particularly its high false-negative rate, which carries important public health implications …

Our objective was to review current large studies of human papillomavirus (HPV) DNA
testing as an adjunct to the Papanicolaou test for cervical cancer screening programs. We …

Key Clinical Points Cervical-Cancer Screening with Human Papillomavirus and Cytologic
Cotesting Cervical cancer screening in the United States should not start until the age of 21 …